Table 4. Outcomes of the study population according to the extended-spectrum β-lactamase/carbapenem resistant Enterobacteriaceae fecal carriage.
| Characteristics | ESBL-E carriage | CRE carriage | Non-ESBL-E/Non-CRE carriage | |
|---|---|---|---|---|
| Number of episode which developed gram negative rods BSI (n/N, %) | 8/38 (21) | 4/30 (13.33) | 11/133 (8.27) | |
| ESBL-E bacteremia (n/N, %) | 3/38 (7.89) | 0 | 3/133 (2.25) | |
| CRE bacteremia (n/N, %) | 1/38 (2.63) | 2/30 (6.66) | 2/133 (1.50) | |
| Non-ESBL-E/Non-CRE bacteremia (n/N, %) | 4/38 (10.52) | 2/30 (6.66) | 6/133 (4.51) | |
| Treatment | ||||
| Standard-of-care (n/N, %) | 30/38 (78.94) | 26/30 (86.66) | 133/133 (100) | |
| Adapted empirical (n/N, %) | 8/38 (21) | 4/30 (13.33) | - | |
| Deescalated targeted (n/N, %) | 4/38 (10.52) | 2/30 (6.66) | - | |
| Escalated targeted | 1/38 (2.63) | 0 | 5/133 (3.75) | |
| Inadequate empirical | 0 | 0 | 5/133 (3.75) | |
| Days of hospitalization (mean ± SD) | 23.34 ± 5.7 | 22.94 ± 5.4 | 22.42 ± 5.21 | |
| Days of antibiotic therapy (mean ± SD) | 19.65 ± 4.19 | 19.25 ± 3.99 | 19.18 ± 3.79 | |
| 14-day mortality among ESBL-E bacteremia (n/N, %) | 2 (5.26) | - | 0 | |
| 14-day mortality among CRE bacteremia (n/N, %) | 0 | 1/30 (3.33) | 0 | |
| 14-day mortality among Non-ESBL-E/Non-CRE bacteremia (n/N, %) | 1/38 (2.63) | 0 | 1/133 (0.75) | |
| Total deaths within 14 days (n/N, %) | 3/38 (7.89) | 1/30 (3.33) | 1/133 (0.75) | |
| 28-day overall mortality (n/N, %) | 4/38 (10.52) | 3/30 (10.00) | 11/133 (8.27) | |
ESBL-E, extended-spectrum beta-lactamase-producing Enterobacteriaceae; CRE, carbapenem-resistant Enterobacteriaceae; SD, standard deviation.